NORWALK, Conn.--Perkin-Elmer announced that, subject to shareholder and final board approval, it plans to distribute a new class of common stock intended to track the separate performance of Celera Genomics, a new business unit formed through an alliance between Perkin-Elmer and Craig Venter, former president of the Institute for Genomic Research, with a mission to become the definitive source for genomic and related biomedical information.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.